Kuppermann BD, Thomas EL, de Smet MD, Grillone LR, for the Vitrase for Vitreous Hemorrhage Study Groups.
Vitrase (hyaluronidase injection) ovine, 200 USP units/mL [package insert].
We will continue to supply the enzyme for Vitrase
but, that said, we did turnover of pounds 6.
is a treatment for the eye condition, severe vitreous haemorrhage, which causes bleeding into the vitreous humour of the eye, leading to sight problems.
The endpoint for determining the efficacy of the Vitrase treatment will be successful treatment of the underlying causes of vitreous hemorrhage.
Based on our clinical experiences to date, Vitrase offers the potential to be the first non-surgical treatment for vitreous hemorrhage.
Results of a previous Phase III study of Vitrase conducted outside of the United States showed a significant difference in the incidence of vitreous hemorrhage clearance for patients with dense hemorrhages, with the highest proportion of dense hemorrhage clearance occurring in the 75 IU dose.
Pioneering development of Vitrase was conducted by scientists at Cedars Sinai Ophthalmology Research Labs who were investigating the impact of various enzymes in the vitreous.
Since that time, ACS has undertaken the clinical development of Vitrase, and in early October received "Fast Track" designation from the U.
Except for historical information contained herein, this press release contains "forward looking statements," such as statements regarding the potential benefit of Vitrase
for the treatment of severe vitreous hemorrhage, progress of the Phase III trials for Vitrase
and timing of availability of preliminary results from the Phase III clinical trials.
Except for historical information contained herein, this press release contains "forward looking statements," such as statements regarding the progress of the Phase III trials for Vitrase
for the treatment of severe vitreous hemorrhage and the Phase II trial for the treatment of diabetic retinopathy and the achievement and reporting of future clinical milestones.